Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Wednesday, May 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. has announced a private placement of common stock, with management members purchasing shares worth $300,000. This investment is seen as a positive signal of confidence in the company's prospects. The funds will support the development of their ARCUS platform for gene editing therapies.
Price reaction · baseline $10.57 (2024-05-07 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
+6.6%
day 1
+3.4%
day 3 · peak
+8.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Management's investment reflects confidence in the company's future.
  • The private placement raises significant capital for development.
  • Precision BioSciences is advancing in gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 8, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination,

Frequently Asked Questions

What is the amount of the stock purchase by management?

$300,000 in a private placement.

What platform does Precision BioSciences use?

They utilize the ARCUS platform for gene editing therapies.

When was the stock purchase announced?

The announcement was made on May 8, 2024.

What does the investment signal about the company?

It reflects management's confidence in the company's future.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform private placement
Last updated: May 8, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →